Globular head-displayed conserved influenza H1 hemagglutinin stalk epitopes confer protection against heterologous H1N1 virus

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Klausberger, Miriam ^a   Tscheliessnig, Rupert ^a,b   Neff, Silke ^a   Nachbagauer, Raffael ^c,d   Wohlbold, Teddy John ^d   Wilde, Monika ^a   Palmberger, Dieter ^a   Krammer, Florian ^d   Jungbauer, Alois ^a   Grabherr, Reingard ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLYSYLLEUCYLARGINYLMETHIONYLVALYLTHREONYLGLYCYLLEUCYLARGINYLASPARAGINYLISOLEUCYLPROLYLSERYLISOLEUCYLGLUTAMYLSERYLARGINYLGLYCYLLEUCYLPHENYLALANYLGLYCYLALANYLISOLEUCYLALANINE; GLUTAMYLSERYLARGINYLGLYCYLLEUCYLPHENYLALANYLGLYCYLALANYLISOLEUCYLALANYL GLYCYLGLYCYLGLYCYLGLYCYLGLYCYL VALYLASPARTYLGLYCYLTRYPTOPHYLTYROSYL GLYCYLTYROSYLHISTIDYLHISTIDYLGLUTAMINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LYSYLVALYLASPARTYLASPARTYLGLYCYLPHENYLALANYLLEUCYLASPARTYLISOLEUCYLTRYPTOPHYLTHREONYLTYROSYLASPARAGINYLALANYLGLUTAMYLLEUCYLLEUCYLVALYLLEUCYLLEUCYLGLUTAMYLASPARAGINYLGLUTAMYLARGINYLTHREONINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VALYLASPARTYLGLYCYLTRYPTOPHYLTYROSYLGLYCYLTYROSYLHISTIDYLHISTIDYLGLUTAMYL GLYCYLGLYCYLGLYCYLGLYCYLGLYCYL ISOLEUCYLGLYCYLASPARGINYLGLYCYLCYSTYLPHENYLALANYLGLUTAMYLPHENYLALANYLTYROSYLHISTIDINE; VALYLTYROSYLGLUTAMYLISOLEUCYLLEUCYLALANYLTYROSYLSERYLTHREONYLVALYLALANYLSERYLSERYLLEUCYLVALYLLEUCYLLEUCYLVALYLSERYLLEUCYLGLYCYLALANYLISOLEUCYLSERINE; EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; EPITOPE MAPPING; FEMALE; HUMAN; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PHYLOGENY; PROTEIN BINDING; SEASONAL INFLUENZA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; MOLECULAR GENETICS; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EPITOPES; FEMALE; FLOW CYTOMETRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84979011884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153579     Document Type: Article

References (54)

1. Carrat F, Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine 2007; 25:6852-62. doi: 10.1016/j.vaccine.2007.07.027 PMID: 17719149
2. Krammer F, Palese P, Steel J. Advances in Universal Influenza Virus Vaccine Design and Antibody Mediated Therapies Based on Conserved Regions of the Hemagglutinin. Curr Top Microbiol Immunol2014. doi: 10.1007/82-2014-408
3. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010; 201:354-62. doi: 10.1086/649428 PMID: 20039806
4. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo. J Virol 2012; 86:6179-88. doi: 10. 1128/JVI.00469-12 PMID: 22491456
5. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. In Vivo Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies. J Virol 2013; 87:8272-81. doi: 10.1128/JVI.00969-13 PMID: 23698304
6. Styk B, Russ G, Poláková K. Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. III. Reactivity with human convalescent sera. Acta Virol 1979; 23:1-8. PMID: 35954
7. Staneková Z, Mucha V, Sládková T, Blaškovičová H, Kostolanský F, Varečková E. Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection: Anti-HA2 antibodies after influenza infection of humans. Influenza Other Respir Viruses 2012; 6:389-95. doi: 10.1111/j.1750-2659. 2011.00328.x PMID: 22236105
8. Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73. doi: 10.1172/JCI41902 PMID: 20389023
9. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, et al. H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination. PLoS ONE 2011; 6:e25797. doi: 10.1371/journal.pone.0025797 PMID: 22039424
10. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang C-Y, et al. Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A Antibodies. Clin Infect Dis 2011; 52:1003-9.doi: 10.1093/cid/cir121 PMID: 21460314
11. Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, et al. H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice. J Virol 2013; 87:4728-37. doi: 10.1128/JVI.03509-12 PMID: 23408625
12. Frank R. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 1992; 48:9217-32. doi: 10.1016/S0040-4020(01)85612-X
13. Pflegerl K, Hahn R, Berger E, Jungbauer A. Mutational analysis of a blood coagulation factor VIII-binding peptide. J Pept Res Off J Am Pept Soc 2002; 59:174-82.
14. Dreyfus C, Ekiert DC, Wilson IA. Structure of a Classical Broadly Neutralizing Stem Antibody in Complex with a Pandemic H2 Influenza Virus Hemagglutinin. J Virol 2013; 87:7149-54. doi: 10.1128/JVI. 02975-12 PMID: 23552413
15. Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, et al. An In Vivo Human-Plasmablast Enrichment Technique Allows Rapid Identification of Therapeutic Influenza A Antibodies. Cell Host Microbe 2013; 14:93-103. doi: 10.1016/j.chom.2013.06.004 PMID: 23870317
16. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly Conserved Protective Epitopes on Influenza B Viruses. Science 2012; 337:1343-8. doi: 10.1126/science.1222908 PMID: 22878502
17. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High FiveTM) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 2010; 45:226-34. doi: 10.1007/s12033-010-9268-3 PMID: 20300881
18. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994; 68:4031-4. PMID: 7514684
19. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates. PLoS ONE 2012; 7:e43603. doi: 10.1371/journal.pone.0043603 PMID: 22928001
20. Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies. J Virol 2013; 87:6542-50. doi: 10.1128/JVI. 00641-13 PMID: 23576508
21. Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014; 32:355-62. doi: 10.1016/j.vaccine.2013.11.036 PMID: 24262313
22. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins. PLoS Pathog 2010; 6:e1000796. doi: 10.1371/journal.ppat.1000796 PMID: 20195520
23. Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 2015; 33:3314-21. doi: 10.1016/j.vaccine.2015.05.038 PMID: 26026378
24. Davies DR, Padlan EA, Sheriff S. Antibody-antigen complexes. Annu Rev Biochem 1990; 59:439-73. doi: 10.1146/annurev.bi.59.070190.002255 PMID: 2197980
25. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination-from allergy to cancer. Expert Opin Biol Ther 2009; 9:493-506. doi: 10.1517/14712590902870386 PMID: 19344285
26. Berglund L, Andrade J, Odeberg J, Uhlén M. The epitope space of the human proteome. Protein Sci 2008; 17:606-13. doi: 10.1110/ps.073347208 PMID: 18359855
27. Ferko B, Katinger D, Grassauer A, Egorov A, Romanova J, Niebler B, et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 1998; 178:1359-68. PMID: 9780256
28. Staczek J, Gilleland HE Jr, Gilleland LB, Harty RN, García-Sastre A, Engelhardt OG, et al. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infect Immun 1998; 66:3990-4. PMID: 9673294
29. Krammer F, Schinko T, Messner P, Palmberger D, Ferko B, Grabherr R. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J Virol Methods 2010; 167:17-22. doi: 10.1016/j.jviromet.2010.03.003 PMID: 20304011
30. Crucell Holland BV. Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses. ClinicalTrials.gov Identifier: NCT01756950 https://clinicaltrials.gov/ct2/show/NCT01756950? term=cr8020&rank=1 (accessed 04/07/2016)
31. Crucell Holland BV. Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge. ClinicalTrials.gov Identifier: NCT01938352 https://clinicaltrials.gov/ct2/show/NCT01938352? term=cr8020&rank=3 (accessed 04/07/2016)
32. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and Immunogenicity of Multimeric-001-a Novel Universal Influenza Vaccine. J Clin Immunol 2012; 32:595-603. doi: 10. 1007/s10875-011-9632-5 PMID: 22318394
33. Sivalingam GN, Shepherd AJ. An analysis of B-cell epitope discontinuity. Mol Immunol 2012; 51:304-9. doi: 10.1016/j.molimm.2012.03.030 PMID: 22520973
34. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med 2015; 7:316ra192-316ra192. doi: 10. 1126/scitranslmed.aad0522 PMID: 26631631
35. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26:D35-40. doi: 10.1016/j.vaccine.2008.07.065 PMID: 19230157
36. Müller GM, Shapira M, Arnon R. Anti-influenza response achieved by immunization with a synthetic conjugate. Proc Natl Acad Sci U S A 1982; 79:569-73. PMID: 6176996
37. Nestorowicz A, Tregear GW, Southwell CN, Martyn J, Murray JM, White DO, et al. Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites. Mol Immunol 1985; 22:145-54. PMID: 2579329
38. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci 2010; 107:18979-84. doi: 10.1073/pnas.1013387107 PMID: 20956293
39. Jerry DJ. Monitoring coupling of peptides to carrier proteins using biotinylated peptide. BioTechniques 1993; 14:464-9. PMID: 8457355
40. Condron MM, Monien BH, Bitan G. Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein. Open Biotechnol J 2008; 2:87-93. doi: 10.2174/1874070700802010087 PMID: 19898686
41. Nagy Z, Rajnavölgyi E, Hollósi M, Tóth GK, Váradi G, Penke B, et al. The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection. Scand J Immunol 1994; 40:281-91. PMID: 8091127
42. Horváth A, Tóth GK, Gogolák P, Nagy Z, Kurucz I, Pecht I, et al. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 1998; 60:127-36. PMID: 9557954
43. Prabhu N, Prabakaran M, Ho H-T, Velumani S, Qiang J, Goutama M, et al. Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection. J Virol 2009; 83:2553-62. doi: 10.1128/JVI.02165-08 PMID: 19109379
44. Mullarkey CE, Boyd A, van Laarhoven A, Lefevre EA, Veronica Carr B, Baratelli M, et al. Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine: Clinical immunology. Eur J Immunol 2013; 43:1940-52. doi: 10.1002/eji.201242922 PMID: 23589155
45. Crowe JE, Krause JC, Blum DL. Influenza virus antibodies and immunogens and uses therefor. Patent publication number: WO2012045001 A2. Patent filing number: PCT/US2011/054340
46. Huang Q, Sivaramakrishna RP, Ludwig K, Korte T, Böttcher C, Herrmann A. Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state. Biochim Biophys Acta BBA-Biomembr 2003; 1614:3-13. doi: 10.1016/S0005-2736(03)00158-5
47. Ekiert DC, Friesen RHE, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-50. doi: 10.1126/science.1204839 PMID: 21737702
48. Tang XL, Tregear GW, White DO, Jackson DC. Minimum requirements for immunogenic and antigenic activities of homologs of a synthetic peptide of influenza virus hemagglutinin. J Virol 1988; 62:4745-51.PMID: 2460640
49. Jackson DC, Tang XL, Brown LE, Murray JM, White DO, Tregear GW. Antigenic determinants of influenza virus hemagglutinin. XII. the epitopes of a synthetic peptide representing the C-terminus of HA1.Virology 1986; 155:625-32. PMID: 2431541
50. Rajnavölgyi E, Nagy Z, Kurucz I, Gogolák P, Tóth GK, Váradi G, et al. T cell recognition of the posttranslationally cleaved intersubunit region of influenza virus hemagglutinin. Mol Immunol 1994; 31:1403-14. PMID: 7823966
51. Gogolák P, Simon Á, Horváth A, Réthi B, Simon I, Berkics K, et al. Mapping of a Protective Helper T Cell Epitope of Human Influenza A Virus Hemagglutinin. Biochem Biophys Res Commun 2000; 270:190-8. doi: 10.1006/bbrc.2000.2384 PMID: 10733926
52. Tharakaraman K, Subramanian V, Cain D, Sasisekharan V, Sasisekharan R. Broadly Neutralizing Influenza Hemagglutinin Stem-Specific Antibody CR8020 Targets Residues that Are Prone to Escape due to Host Selection Pressure. Cell Host Microbe 2014; 15:644-51. doi: 10.1016/j.chom.2014.04.009PMID: 24832457
53. Terajima M, Cruz J, Co MDT, Lee J-H, Kaur K, Wilson PC, et al. Complement-Dependent Lysis of Influenza A Virus-Infected Cells by Broadly Cross-Reactive Human Monoclonal Antibodies. J Virol 2011; 85:13463-7. doi: 10.1128/JVI.05193-11 PMID: 21994454
54. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51. doi: 10.1038/nm.3443 PMID: 24412922